期刊
CURRENT MEDICINAL CHEMISTRY
卷 23, 期 25, 页码 2874-2891出版社
BENTHAM SCIENCE PUBL LTD
DOI: 10.2174/0929867323666160321121138
关键词
Antidiabetics; insulinomimetics; PTP1B; vanadium complexes; speciation; drug design; molecular modeling
Public academic research sites, private institutions as well as small companies have made substantial contributions to the ongoing development of antidiabetic vanadium compounds. But why is this endeavor not echoed by the globally operating pharmaceutical companies, also known as Big Pharma? Intriguingly, today's clinical practice is in great need to improve or replace insulin treatment against Diabetes Mellitus (DM). Insulin is the mainstay therapeutically and economically. So, why do those companies develop potential antidiabetic drug candidates without vanadium (vanadium-free)? We gathered information about physicochemical and pharmacological properties of known vanadium-containing antidiabetic compounds from the specialized literature, and converted the data into explanations (arguments, the pros and cons) about the underpinnings of antidiabetic vanadium. Some discoveries were embedded in chronological order while seminal reviews of the last decade about the Medicinal chemistry of vanadium and its history were also listed for further understanding. In particular, the concepts of so-called noncomplexed or free vanadium species (i.e. inorganic oxido-coordinated species) and biogenic speciation of antidiabetic vanadium complexes were found critical and subsequently documented in more details to answer the question.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据